According to a new RNCOS report titled “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022”, the total immuno-oncology market will be worth approximately US$ 68.9 Billion by 2019, rising to US$ 104 Billion by 2022, as the penetration of immune checkpoint inhibitors will increase.

As per RNCOS, latest analysis reports, the approval and uptake of immuno-oncology products is set to boom due to increased recognition of their long and durable tumor responses, which are similar to targeted therapies. With the associated advantages, such as higher specificity and effectiveness as compared to other drug forms; immuno-oncology therapies have become highly attractive for the pharmaceuticals companies, who are rapidly shifting their focus towards this field. Moreover, these medications have shown efficacy in a wide variety of indications and are not associated with the adverse side effects produced by traditional chemotherapy.

Immuno-oncology products have exhibited comparable efficacy and safety profiles, so their commercial success will largely rest on the speed with which they enter the market, their clinical and commercial positioning, target patient populations, and the marketing power of the relevant pharmaceutical company.

Ono/Bristol-Myers Squibb’s Opdivo and Schering Plough/Merck and Co.’s Keytruda are predicted to be the highest-selling immuno-oncology drugs. Both therapies, which are PD-1 inhibitors, will achieve impressive sales due to the fact that they will be first-to-market in many indications, transcending competition such as Roche’s atezolizumab and AstraZeneca’s durvalumab. Although Keytruda will have sales in more tumor types than Opdivo, the indications in which the latter will have advantage over its competitors will have the largest drug-treated populations, such as non-small cell lung cancer. However, the opportunities for late-to-market entrants will still remain, despite the market dominance of a small number of products.

These factors, plus strategies of the pharmaceutical companies to enter the market, their clinical and commercial positioning, target patient populations, and the marketing power of these companies will push the global Immuno-oncology market ahead.

RNCOS has over a decade of experience in Healthcare Industry Reports. We can act as a potential growth partner in all your business endeavors, such as product launching, geographic expansion, sales improvement, distributor/retailer tie-ups etc. Furthermore, RNCOS can help make your business flourish by studying the market dynamics and devising the right strategies.

Feel free to download the latest sample: http://rncos.viewpage.co/Immuno-Oncology-Market-Global-Forecast-to-2022

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.